Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 NFXQcYdHfW6ldHnvckBCe3OjeR?= M3SzfFIh|ryP NH;VSVEyKGh? NIrNe4hqdmirYnn0d{B1cGViTD3EU3BCKCh{MNMg{txOMS2rbnT1Z4VlKHS{YX7zbYVvfCCHUluxM|IheGixc4Doc5J6dGG2aX;uxsA> M{P2fFI3OzZ|MUmx
C2C12 NFr3SHRHfW6ldHnvckBCe3OjeR?= MV6xxsDPxGdxbXy= NWjuToU4OcLiaB?= M{f6TIFjd2yrc3jld{BkgXSxa3nu[UBz\WynYYPlJIZzd21iQ{LDNVIhdXmxdIXi[ZM> MkjqNlYzQTF{N{m=
MEFs WT NYfCeYIzTnWwY4Tpc44hSXO|YYm= MV61xsDPxE1? NWH2OVl7OjBibXnu NYDaUFNF[2G3c3XzJJJme2mmZX70JIVvgnmvZYOgd5VkcCCjczDORWdVNUeIUDygeI8h\GmoZoXz[UBj[WOtIITvJJRp\SCHUh?= MXiyOlE6PjB{Mx?=
MEFs VAMP7 KO MVTGeY5kfGmxbjDBd5NigQ>? MonpOeKh|ryP NEDj[IMzOCCvaX6= NEHLc3Rk[XW|ZYOgdoV{cWSnboSg[Y57gW2nczDzeYNpKGG|IF7BS3QuT0[SLDD0c{BlcW[odYPlJIJi[2tidH:geIhmKEWU M4jrZ|I3OTl4MEKz
SMCs Mo\hSpVv[3Srb36gRZN{[Xl? NYG1b|JJOTEEoNM1[{9udA>? NWS1c4o3OC1zMjDo M3K1bGROW09? MXrzbI94eyCjIITy[Y5lKHSxd3Hy[JMh[SCqaXfo[ZIh[2:wY3XueJJifGmxbjDv[kB1cGViRWKvV3IhdmW2d3;yb{BqdiC2aHWgdIVzcW63Y3zlZZIh[XKnYdMg M2W5RVI3OTd{MEiw
SMCs M4\iW2Z2dmO2aX;uJGF{e2G7 MoTtNVDDqML3Zz;tcC=> M2S4PFAuOTJiaB?= M2P6bGROW09? MYnjZZV{\XNiYTD0doFve2mnboSgR4EzM8LicnXs[YF{\SCocn;tJJRp\SCHUj;TVuKh Mk\FNlYyPzJyOEC=
HEMC-1 NIfuNlJHfW6ldHnvckBCe3OjeR?= MkD0NE4yyqEEtXevcYw> NHrvZ|EzPMLiaB?= NVf2bZE1[2G3c3XzJIEhcGmpaHXyJIlvcGmkaYTvdpkh\W[oZXP0JI9vKGW6b3P5eI9{cXNidHjhckBvd2OxZHH6c4xm M13KflI2QTd{N{W5
HUVEC MnHhSpVv[3Srb36gRZN{[Xl? NULzdohGOTEEoN88US=> NESydpMyyqCq NWjrcFU2TE2VTx?= MV\hZo9tcXOqZYOgbJlxd3irYT3pcoR2[2WmIILlcIVie2Vib3[gRXRRKG[{b32gZZBq[2GuIHHu[EBj[XOxbHH0[ZJidCC|dYLmZYNmew>? MlXmNlU6PTZ7OEi=
HUVEC NG\aSWVHfW6ldHnvckBCe3OjeR?= MXuxNOKh|ryP MUexxsBp MlXxSG1UVw>? M3TzT4lv[3KnYYPld:KhfGinIH71cYJmeiCjbnSgbY51\W6|aYT5JI9nKG[udX;y[ZNk\W62IHHy[YF{KGW|cHXjbYFtdHliaX6gdIVzcW63Y3zlZZIhe3CjY3W= NXrOPFI1OjV7NU[5PFg>
Caco-2 MnjLSpVv[3Srb36gRZN{[Xl? MVqyMlUh|ryP MVmzNEBucW5? MkDpZZR1\W63YYTld{B1cGViVFfGMe6zOS2vZXTpZZRm\CCrbnPy[YF{\SCrbjDTSXJVKG[3bnP0bY9v MXOyOVk2PDl|MR?=
NRK MkmxSpVv[3Srb36gRZN{[Xl? M4Lv[FIxOOLChX7nM41t NGPa[XM16oDHaB?= MnvkSG1UVw>? MmnKdoV{[3WnczDtbZRwfGmlIIDyc4dz\XO|aX;u NFjSbmczPTl2OEW4Oi=>
HeLa MWTGeY5kfGmxbjDBd5NigQ>? NVzLVlBzOjBy4pEFcocwdWx? NVLxRnBQOyCq MW\EUXNQ M4HC[Ilv\HWlZYOgeIhmKGG{dHnmbYNq[WxiYoLlZYsufXBib3[geIhmKEexbHfpJINwdXCuZYi= MXWyOVk1QDV6Nh?=
COS MWLGeY5kfGmxbjDBd5NigQ>? NHLjdWUyKM7:Zz;tcC=> MXmzJIg> NV:3b4xX[2:vcHzleIVtgSCmaYPw[ZJ{\XNidHjlJGFRNTFic3nncoFtyqB? M3jzSFI2QTF3OUCw
DF1  MkC2SpVv[3Srb36gRZN{[Xl? MX2xxsDPxE4EoB?= MYK0PEBp NWD0W|hvTE2VTx?= NV\Pcnhm\Gm|cHXyd4V{yqC2aHWg[Zhw\2Wwb4XzJGNUT2GuTlHjWFIheHKxdHXpci=> MW[yOVgxPzB3NB?=
nHDFs  NYXX[JN5TnWwY4Tpc44hSXO|YYm= Mn7kNeKh|ryPwrC= NFnyT5YzyqCq NEfFcItxemW4ZX70d{B1cGViYYPz[Y1jdHlib3[gZ5l1d3OxbHnjJINw[XRicILveIVqdnNib370c{BId2ypaTDt[Y1jemGwZYO= Ml\NNlU4PzJ4MU[=
FRT  NF;tOJZHfW6ldHnvckBCe3OjeR?= MnjEOUDPxGdxbXy= M4H5VVLDqGh? NXPqVZNQ[myxY3vzJJRz[W[oaXPrbY5oKHSqcn;1[4ghfGinIFfvcIdqKGOxbYDs[Zgh[nliaX7obYJqfGmwZzDFVk11dy2Jb3znbUB1emGwc4DvdpQ> NY\nenNuOjV5NkexNVU>
FRT  NHjYOJFHfW6ldHnvckBCe3OjeR?= MXm1JO69\y:vbB?= NHrBepAzyqCq NGX1WotxemW4ZX70d{B1cGViaX7jdoVie2ViaX6gZ4xm[X[nZDFOtUB{fWK3bnn0d{B4cGWwIGvOZUteccLid3HzJJJm\HWlZXS= M3HYd|I2PzZ5MUG1
HepG2  MmLOSpVv[3Srb36gRZN{[Xl? MY[x5qCKyrWPwrC= M4LzPVI1KGh? M2DVW2ROW09? M4DjXoRm[3KnYYPld{B1cGVibHX2[Ywhd2ZiUGjSJI1TVkF? M1\6NVI2PjF4NUm3
SMCs MlLUSpVv[3Srb36gRZN{[Xl? MnX0Ne69\y:vTB?= Mo\6N{Bp NXu2S5ps[WOldX31cIF1\XNiQ17QXVIheHKxdHXpckBqdiC2aHWgSXIh[2:vcHHyeI1mdnRiYX7kJI5wKGyxbnfldkBkdy2ub3PhcIl7\WRid3n0bEB1cGViR3;s[4khdWG{a3XyxsA> NX:wdXJNOjV3OEm0NlU>
OB-6 MoPLRZBweHSxc3nzJGF{e2G7 M37zXFIvP8LizszN Moq3OFghcA>? M3u3VYlv\HWlZYOgZZBweHSxc3nz NWPuZVVWOjV3M{K0PFA>
iPSC-CMs  M3npfmZ2dmO2aX;uJGF{e2G7 MlXyOVAxKG6pL33s MY[0PEBp MU\pcoNz\WG|ZYOgeIhmKGmwdHXud4l1gSCxZjD0bIUhcGmpaHXyJI1w[mmuaYT5JGxCVVC|IHH0JJRp\SClb4P0JI9nKHSqZTDsc5dmeiCvb3LpcIl1gSC|cHXjbYV{ NHXYNFgzPTR6OE[2Oi=>
SP-Nluc NWCzfYpKTnWwY4Tpc44hSXO|YYm= MXe1JI1oN22O NGfucos3KGh? M{LIRmROW00EoB?= M1zjVoNifXOnczDhckBqdmO{ZXHz[UBqdiC{ZYDvdpRmeiCjY4Tpeol1gSCrbjD0bIUheGG{YYPpeIU> MV6yOVM6Ojl7OB?=
PEXEL-Nluc NI\y[ZlHfW6ldHnvckBCe3OjeR?= MkLQOUBu\y:vTB?= M1TFfVYhcA>? MXTEUXNQyqB? NEPEPHZk[XW|ZYOgZY4hcW6lcnXhd4UhcW5icnXwc5J1\XJiYXP0bZZqfHliaX6geIhmKHCjcnHzbZRm NGL4RXozPTN7Mkm5PC=>
H1299 NWTJR49mTnWwY4Tpc44hSXO|YYm= NX3tO5RlOTBizsznM41t MmHwNlQhcA>? NFPyeYdqdmS3Y3XzJIF2fG:yaHHnfeKh NYrsR|c4OjV|OEi5O|A>
MDA-MB-231 NVvYeHhlS2WubDDWbYFjcWyrdImgRZN{[Xl? NXznUmF7OOLCk{WwJO69\y:vTB?= MV20PEBp M3LUbGVEPTEEoE2gNE4xOTZiwsXnM41N NXPnSG9SOjV|NU[1Olc>
MDA-MB-231 MXHBdI9xfG:|aYOgRZN{[Xl? M{LqZ|AvOSEQvHevcWw> MoS3OEBp M4DFe4lv\HWlZYOgZZBweHSxc3nz M3zz[VI2OzV4NU[3
MDA-MB-231 M1jBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr6NE4xOS9yLkC1JO69\y:vTB?= M4\VV|I1KGh? NFTNemZqdmO{ZXHz[ZMhfGinIH\yZYN1cW:wIH;mJJN2[i2JMTDj[YxtKGSnYoLpdy=> Mm\XNlU{PTZ3Nke=
MDA-MB-231 MY\BdI9xfG:|aYOgRZN{[Xl? NG[5eYYxNjB34pETNUDPxGdxbVy= NEja[JUzPCCq NW\yWYZPcW6mdXPld{BRSVKSIDjwc4x6KEGGUD3ybYJwe2VicH;sfY1memG|ZT2xLUBkdGWjdnHn[S=> M4jYOlI2OzV4NU[3
MDA-MB-231 MV7GeY5kfGmxbjDBd5NigQ>? MkPvNQKBmzVyIN88[{9uVA>? M2jReVI1KGh? NWTie|FzcW6qaXLpeJMhfGinIH\vdo1ifGmxbjDv[kA{TCCjbnSgNmQh[2:ub37p[ZM> MlriNlU{PTZ3Nke=
A172 NUHDdoZ{TnWwY4Tpc44hSXO|YYm= Mn3VNVDDqM7:Zz;tcC=> MnHmOOKhcA>? M{XYUGROW00EoB?= NXPDdFJXemW|dXz0d{BqdiC2aHWgdoV1em:pcnHk[UB1emGwc4DvdpQhd2ZiZnz1c5Jme2OnboSg[5JidnWuZYO= NXj0dHQ4OjV{M{m1NFc>
KMS-6 NIT5emJHfW6ldHnvckBCe3OjeR?= MmHBNeKh|ryPwrC= MmS0NlQhcA>? MVjlfIhq[mm2czDoZYxnKHSqZTDz[YNz\XSrb36gc4Yh\2GuYX7pck1NUSCjczDkbYQhfGinIHPvcpRzd2x? MWmyOVIzQTF{Nh?=
MEC NWG4VIlTTnWwY4Tpc44hSXO|YYm= NYX1Z2IyOSEQvF2= NFTYbHMyNjViaB?= NWX4fGlq[2G3c3XzJIEh\HKjbXH0bYMh\GWlcnXhd4UhcW5idHjlJJN2em[jY3WgWmVITlJ{ MVKyOVIzQDhzNR?=
HEK293/hERG M3rkfWZ2dmO2aX;uJGF{e2G7 M{naNlExyqEQvF2= MYGxxsBp M1rO[pJme3WudIOgbY4h[SC2aX3lMYRmeGWwZHXueEBz\WS3Y4Tpc44hdWG2dYLlJIhGWkdicILveIVqdsLi NX;1TYp5OjV{MUi0Olk>
RBE4 M{DZO2Fxd3C2b4Ppd{BCe3OjeR?= M3TJ[FLDqM7:TR?= M4rkc|PjiJN{NNMgbC=> NWm1S5docW6mdXPld{BieG:ydH;zbZMhfGmvZTDk[ZBmdmSnboTsfS=> MVqyOVEzQDB{NR?=
RBE4 NVTRdIJYTnWwY4Tpc44hSXO|YYm= NFjOXHQzyqEQvF2= NVfiZoM2O+LCk{K0xsBp NI\LTG9qdmO{ZXHz[ZMhfGinIGjCVFEheHKxdHXpckBt\X[nbIOgZYZ1\XJiMzDhcoQhPsLiaDDv[kB1emWjdH3lcpQ> M{i5UFI2OTJ6MEK1
RBE4 NHrLPHJHfW6ldHnvckBCe3OjeR?= MoG5NuKh|ryP NGfMO|M{6oDVMkVCpIg> MYPpcoNz\WG|ZYOgZYN1cX[nIHPhd5Bie2VvMUKgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=> NIjhdIgzPTF{OECyOS=>
RBE4 NV7RTZhSTnWwY4Tpc44hSXO|YYm= NUXHOnk6OsLizszN M{m1VlPjiJN{NNMgbC=> NYDPTmlZcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gVm9UKHSrbXWt[IVx\W6mZX70cJk> MYSyOVEzQDB{NR?=
RBE4 M{fBVWZ2dmO2aX;uJGF{e2G7 M3u4TVLDqM7:TR?= MV:z5qCUOjUEoHi= M4m0Zolv\HWlZYOgZUBl\WyjeXXkJIRmeGyndHnvckBw\iC2aHWgSXIhS2F{K9MgZ49vfGWwdDDheEA3yqCqIH;mJIlv[3WkYYTpc44he2mpbnnmbYNidnSueR?= MYqyOVEzQDB{NR?=
RBE4 M3SxSGZ2dmO2aX;uJGF{e2G7 NEK3TFkzyqEQvF2= M2jjWFPjiJN{NNMgbC=> NWnP[FVvcW6mdXPld{BidiCxdnXycI9i\CCxZjDDZVIsyqCrbjD0bIUhdWm2b3Poc45lemmjIHnuJJRp\SCoaYLzeEA3yqCqIH;mJIlv[3WkYYTpc44hMHEkgJm85qCKOC5yMEGpJIJ2fCCFYUKrxsBt\X[nbIOgbY4hfGirczDvdodidmWubHWg[IVkemWjc3XkJIFnfGW{IEGyxsBpKG:oIHnuZ5Vj[XSrb36= MlXkNlUyOjhyMkW=
Huh-7  Mn3PSpVv[3Srb36gRZN{[Xl? NX;LVHJJOc7:Zz;tUC=> NX7wdHNwO+LCk{K0xsBp M{HnTIlv[3KnYYPld{B1cGVibHX2[Ywhd2ZiQWDFNUBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MX[yOVAzPjF5NB?=
HepG2  NITuZYVHfW6ldHnvckBCe3OjeR?= MVux{txoN22O M{nWPVPjiJN{NNMgbC=> M4PvSYlv[3KnYYPld{B1cGVibHX2[Ywhd2ZiQWDFNUBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MmnGNlUxOjZzN{S=
H838-LKB1 MVvGeY5kfGmxbjDBd5NigQ>? M4\keVMxyqCwZz;tcC=> NGXtdJcyOi9zODDo NX;3WYw{cW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDCbXDDqA>? MV[yOVAyOTB6Mh?=
H838-KDLKB1  NUG0NpV1TnWwY4Tpc44hSXO|YYm= NWLiTmZPOzEEoH7nM41t NUfOZ2N6OTJxMUigbC=> NUe2R3htcW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDCbXDDqA>? M1HBVFI2ODFzMEiy
H838-KDLKB1  M3LGSWZ2dmO2aX;uJGF{e2G7 NYi5fHpnOzEEoH7nM41t NVrifmtbOTJxMUigbC=> NXTxfYZ[cW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdIhwe3Cqb4L5cIF1\WRiZVnGNu6yKCiyaH;zdIhwNWWLRkNOtUk> MUmyOVAyOTB6Mh?=
3T3-L1 MV\GeY5kfGmxbjDBd5NigQ>? M{jhVlUh|rypL33s NULBbpY4OzBibXnu M2LLcY1qdWmlczD0bIUh\W[oZXP0d{Bw\iCrboP1cIlvKGGwZDDjZZV{\XNicn;ieZN1KHCqb4PwbI9zgWyjdHnvckBw\iCDa4SgLHNmeiB2N{OpJIFv\CCyaH;zdIhwenmuYYTpc44hd2ZiQWOxOlAhMFSqcjC2OFIh[W6mIGPldkA2QDhr M1;kfFI1QDR|OEK3
3T3-L1 NIP2OWNHfW6ldHnvckBCe3OjeR?= MVq1JO69\y:vbB?= NXjHc|hVOzBibXnu MXny[YNieGm2dXzheIV{KGmwc4XsbY4h[WO2aX;uJJdqfGhicnXzdIVkfCC2bzDy[Yd2dGG2aX7nJGFsfCCjY4Tpeol1gSCjbnSgRXMyPjBicHjvd5Bpd3K7bHH0bY9v NGD1bWkzPDh2M{iyOy=>
3T3-L1 NU\n[2JYTnWwY4Tpc44hSXO|YYm= NFHHUm42KM7:Zz;tcC=> M3rWUlMxKG2rbh?= MY\jZZV{\XNicnX2[ZJ{cWKuZTDy[YRqe3S{aXL1eIlwdiCxZjDHUHVVPA>? MnfENlQ5PDN6Mke=
3T3-L1 MVLGeY5kfGmxbjDBd5NigQ>? NGfZbHk2KM7:Zz;tcC=> NVyw[4h[OcLiaB?= NHnaZ2dk[XW|ZYOgdoVlcXO2cnnieZRqd25ib3[gS2xWXDRiYoX0JI5wfCCrbnPy[YF{\SCrbjDncJVkd3OnIIXweIFs\Q>? NEPKT2EzPDh2M{iyOy=>
3T3-L1 NWPOS5dMTnWwY4Tpc44hSXO|YYm= M3jNW|Uh|rypL33s M{LXblHDqGh? NEP4c2Rk[XW|ZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJJRp\SCIb4jPNUB1emGwc3PybZB1cW:wIH\hZ5Rweg>? NFzzfnMzPDh2M{iyOy=>
HeLa  MV3GeY5kfGmxbjDBd5NigQ>? NV6xV|diPSEQvHevcYw> MX2zJIg> NFHZTXhk[XW|ZYOgcpVkdGWjcjDlfINtfXOrb36gc4YhfGinIF\vfG8yKHS{YX7zZ5JqeHSrb36g[oFkfG:{IHHu[EBl\WO{ZXHz[ZMhfHKjboPjdolxfGmxbjDv[kBHd3iRMT3y[Yd2dGG2ZXSg[4Vv\XN? NIfWVFEzPDh2M{iyOy=>
HEK293 MWLGeY5kfGmxbjDBd5NigQ>? MUW1xsDPxGdxbXy= NIfhcGIyOsLiaB?= M{CxUoFjd2yrc3jld{BEVUFvaX7keYNm\CCFUlXMSFIhe2WlcnX0bY9v NHzJbpczPDZ6N{SzNS=>
COS-1 NX3oepBpTnWwY4Tpc44hSXO|YYm= MXe1JOK2\y:vbB?= Ml25NlQhcMLi NIrZd5Vz\XO2cnnjeJMhdG:lYXzpfoF1cW:wIH;mJG5DKGmwIITo[UBx\XKrboXjcIVieiC{ZXfpc47DqA>? NYrEbmQ{OjR4N{G3OVE>
PRP M3LkemZ2dmO2aX;uJGF{e2G7 M2L6OlExKM7:TR?= MkfIZYJzd2ejdHXzJHNFTi1zzsGtcYVlcWG2ZXSgR3hEWjdiZYj0[ZJv[WyrenH0bY9vyqB? M{OxOVI1PjZ6N{Ww
RAW264.7 Mn\DRZBweHSxc3nzJGF{e2G7 NUTlVXFKPCEQvF2= NFnVdI81QCCq NIDmVGZifHSnboXheIV{KHSqZTDpcohq[mm2aX;uJI9nKG:6LVzEUE1qdmS3Y3XkJIFxd3C2b4Ppd{BidmRidHjlJIZi[2muaYTheIlwdiCxZjDjbI9t\XO2ZYLvcEBm\m[udYigZpkhSWNvaFWtNVhCNU6KMh?= MVeyOFY{QTB|Mh?=
MDMs NF7OUYVCeG:ydH;zbZMhSXO|YYm= MXKxNQKBkc7:Zz;tcC=> NHrCXHMyOi9zNTDo NXy4WmVucW6mdXPld{BieG:ydH;zbZM> NVzVdGdSOjR3NU[2PVU>
PMHs  NHPG[WlHfW6ldHnvckBCe3OjeR?= M3SxNlEx6oDVMkFihKnPxGdxbXy= MX[yOQKBkWh? NX\wV5dyTE2VTx?= M4rve4lv\HWlZXSgSXIhe3S{ZYPz MViyOFQxPzJ2Mh?=
PMHs  MkH0RZBweHSxc3nzJGF{e2G7 MkHjNVDjiJN{MPMAje69\y:vbB?= MVeyOQKBkWh? MkP1SG1UVw>? MULpcoNz\WG|ZYOgZ4VtdCCmZXH0bC=> MUmyOFQxPzJ2Mh?=
HEK293/tau MoD2SpVv[3Srb36gRZN{[Xl? MnLBOUDPxE1? Mn2zNU8zNzRiaB?= Mm\ZbY5lfWOnczDHc4xocSCocnHncYVvfGG2aX;uxsA> MWmyOFM3QDB6OR?=
HEK293/tau NHHsT4RHfW6ldHnvckBCe3OjeR?= MVm1JO69VQ>? MmPCN{Bp MYTpcoR2[2W|IITheUBpgXCncoDoc5NxcG:{eXzheIlwdg>? Mkj6NlQ{PjhyOEm=
ADF MVLGeY5kfGmxbjDBd5NigQ>? NYn1[okzOTBizszN MXWxOkBp MUXpcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> MYWyOFIzQDJ|Mh?=
U373  MlT4SpVv[3Srb36gRZN{[Xl? MYixNEDPxE1? NHSxVYgyPiCq M2X5WolvcGmkaYTzJJRp\SCcblPsNk1qdmS3Y3XkJJRz[W6|bH;jZZRqd25ib3[gR3JV Ml3KNlQzOjh{M{K=
RKO-HIPK2i M3rhZWZ2dmO2aX;uJGF{e2G7 MXWxNEDPxE1? MmS2NVYhcA>? M1XFT4lvcGmkaYTzJJRp\SCcblPsNk1qdmS3Y3XkJJRz[W6|bH;jZZRqd25ib3[gR3JV M4nIWVI1OjJ6MkOy
ADF  MlPPSpVv[3Srb36gRZN{[Xl? MXuxNEDPxE4EoB?= NVLubHJiPiCq MVXpcZBicXK|IITo[UBFSyCjY4TpeoF1cW:w MmDGNlQzOjh{M{K=
Huh7 MoP2SpVv[3Srb36gRZN{[Xl? MlrUOUDPxGdxbXy= MmL4OEBp MkmxZYJwdGm|aHXzJJRp\SC|ZXPy[ZRqd25ib3[gJIlvfHKjY3XscJVt[XJiQYDvRi=> M1noWlI1OTByMUSw
Huh7 Ml7DSpVv[3Srb36gRZN{[Xl? NWjrTYx2PSEQvHevcYw> M3rOZlEhcA>? NX\kU5hD[2G3c3XzJIEhe2mpbnnmbYNidnRiaX7jdoVie2ViaX6gRZBwSi2lcnXzZ4VvfHN? M{jhRVI1OTByMUSw
Huh7 M1n3T2Z2dmO2aX;uJGF{e2G7 MU[15qCUOTEEoH7nM41t NWOxd5ZNOTJiaB?= MYnpcoNz\WG|ZYOgRZBwSi2lcnXzZ4VvfHNid3n0bI92fCCrbnjpZol1cW6pIIPlZ5JmfGmxbh?= M1e3blI1OTByMUSw
BAECs MUjGeY5kfGmxbjDBd5NigQ>? NVTYcXRkPSEQvHevcYw> Mo\MNE01KGh? MkPKbY5lfWOnczD0bIUhemGyaXSg[IVxcG:|cHjvdplt[XSrb36gc4Yh\U6RUzDheEBU\XJzMUe5 MYKyOFA5PTJ{NR?=
Macrophages NF;ZTldHfW6ldHnvckBCe3OjeR?= NHjxTWY4OSEEtV2= NW[xcHNKPiCq M{fNcYlvcGmkaYTzJIx2dmG|aX6gbY51\XKwYXzpfoF1cW:wwrC= NHftUngzPDB|OUe0NC=>
Colo 205 NIe1WJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L6flAuPSEQvHevcWw> NE\mOGQ1QCCq MVHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiC|dYPw[Y5{cW:wIHP1cJR2emW|IIfpeIgh[W5iZYP0bY1ifGWmIFnDOVAhd2ZifkG1JI5oN22O NGDFRVczOzl5M{m5Oi=>
Colo 205 NI\HWYhHfW6ldHnvckBCe3OjeR?= M{jmUFAvODF{LUCuNFI2KM7:Zz;tUC=> M2\tcFE1KGR? NIHwdmtz\WS3Y3XzJJRp\SClbH;uc4dmdmmlaYT5JI9nKEOxbH:gNlA2KEOVQ4O= MXWyN|k4Ozl7Nh?=
Colo 205 M2rSSGFxd3C2b4Ppd{BCe3OjeR?= NX\zT3lwOC5zIN88[{9uVA>? NIDjfHQxNTJ2IHi= NHu1dWNqdmS3Y3XzJIFxd3C2b4Ppd{Bw\iCFb3zvJFIxPSClZXzsd{BqdiC|dYPw[Y5{cW:wIHP1cJR2emW| MVKyN|k4Ozl7Nh?=
Colo 205 Mn;SSpVv[3Srb36gRZN{[Xl? NYXwRlR[OC5yMUWg{txoN22O NIS3ZYgzPCCq M3HjTYlv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gSXIhe3S{ZYPzMZJmdGG2ZXSg[4Vv\XN? M13i[VI{QTd|OUm2
Colo 205 MWjGeY5kfGmxbjDBd5NigQ>? NY\NdGhPOC5yMUWg{txoN22O MVeyOEBp MYnpcohq[mm2czD0bIUh[WO2aY\peJkhd2ZiTV3Qdy=> NXPidnJkOjN7N{O5PVY>
IBRS2 Mkf6SpVv[3Srb36gRZN{[Xl? M4fPSFUh|rypL33s NFrtOpIxNjViaB?= MV;EUXNQ NGLyXJBlcXO{dYD0d{B1cGViRWLHTWMh[W6mIFfvcIdqyqB? MljUNlM6PjN3M{S=
IBRS2 NWPOdJpzTnWwY4Tpc44hSXO|YYm= Ml3EOUDPxGdxbXy= M3z3PVAvPSCq NF;ZcFVFVVOR NHnGbFlmdmijbnPld{BHVUSYIHnu[oVkfGmxbh?= MXOyN|k3OzV|NB?=
HeLa MkjqSpVv[3Srb36gRZN{[Xl? MXGyJO69VQ>? NFvWV|czKGkEoB?= MlfxZZR1\W63YYTld{B1cGViVF7GMYlv\HWlZXSgd4VkemW2aX;uJI9nKEmOLUG1 NFTVNGkzOzl3MEi5Ni=>
HFS  MnW0SpVv[3Srb36gRZN{[Xl? NX;iOJk{OC1zIN88[{9udA>? MWOyOEBp NGi3TFFIVFSSIHX4dJJme3Orb36gdoVi[2inczDhJJBt[XSnYYWgZZQh[2:wY3XueJJifGmxboOgZZMhdG:5IHHzJFAvODFiwsXnM41t M1f2eVI{QDl2NkOz
HFS  MofSSpVv[3Srb36gRZN{[Xl? NX7lcW1QOC5yMTFCuYcwdWx? NGe2U20zPCCq NIHRUXRqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4Yh\2y7Y3;zdIhqdmexbHnwbYQhe3mwdHjhd4Uh\2WwZYOgZZQhPiCq NHTIcFEzOzh7NE[zNy=>
OVCAR-3 M{PVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\aNgKBmzF3wrFOwG3DqA>? Ml\zNlTDqGh? NGjJdnlqdmS3Y3XzJIEhdG:|czDv[kBk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7wrC= NImwdWwzOzh{Nkm2OC=>
OVCAR-3 NEHHb5JHfW6ldHnvckBCe3OjeR?= NHnzXI0y6oDVMUZCpO69VcLi NILXUIozPMLiaB?= M3jweYlv\HWlZYOgcpVkdGWjcjDkZY1i\2V? NFr1NYgzOzh{Nkm2OC=>
OVCAR-3 M1rEU2Fxd3C2b4Ppd{BCe3OjeR?= MlW4NU0yOMLizszN M{fX[VQhcA>? MUPpcoR2[2W|IITo[UBi[3SrdnH0bY9vKG:oIHHwc5B1d3Orcz3y[YxifGWmIIDyc5RmcW6| M3r2NVI{QDJ4OU[0
OVCAR-3 M1\qOWFxd3C2b4Ppd{BCe3OjeR?= M{jYOFExyqEQvF2= MWSyOOKhcA>? NFHWbnhqdmS3Y3XzJIFkfGm4YYTpc44hd2ZiY3HzdIF{\XN? NUXwN5pKOjN6Mk[5OlQ>
OVCAR-3 MWXGeY5kfGmxbjDBd5NigQ>? MnPrNgKBmzFywrFOwG0> MX2yOOKhcA>? MmDqbY5lfWOnczDkbZNzfXC2aX;uJI9nKHSqZTDtbZRw[2ixbnTybYFtKHS{YX7zcYVu[nKjbnWgdI91\W62aXHs MXOyN|gzPjl4NB?=
OVCAR-3 M2HuOGZ2dmO2aX;uJGF{e2G7 NGe1VYUy6oDVMUFCpO69VQ>? NXrtc2wyOjUEoHi= MVPpcoR2[2W|IH\vdo1ifGmxbjDv[kBz\WGldHn2[UBwgHmpZX6gd5Bm[2mncx?= M2D4clI{QDJ4OU[0
OVCAR-3 M1zQPGZ2dmO2aX;uJGF{e2G7 NVuyc4JMOeLCk{GwxsDPxE1? NFXKfYIzPMLiaB?= NF7MTHFqdmirYnn0d{Bk\WyuIHHkbIV{cW:wIHHu[EBucWe{YYTpc44> NV3nPFdjOjN6Mk[5OlQ>
MKN45 NIf3R2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPtTWM2ODxyLkCwNUDPxGdxbXy= NULVSWR{OjN5OUOzOFI>
LOVO M4DQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TQ[WlEPTB;MD6xNkDPxGdxbXy= NX[3ZllzOjN5OUOzOFI>
A549 M3;jcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3FV5BLUUN3ME2wMlA1KM7:Zz;tcC=> MkThNlM4QTN|NEK=
MDA-MB-435 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRDBwMECxJO69\y:vbB?= M1rpelI{Pzl|M{Sy
HepG2 Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\CTWM2ODxyLkCwNUDPxGdxbXy= NWnwPItrOjN5OUOzOFI>
HL-60 NYj1Oph4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRDBwMECxJO69\y:vbB?= M4T1PFI{Pzl|M{Sy

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[5]
+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method: HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID